Abstract: According to one embodiment, a display device includes a display panel having a display area, a first substrate opposed to the display panel, an adhesive layer arranged between the display panel and the first substrate, a first electrode formed at the first substrate in a peripheral area arranged along at least a part of an outer edge of the display area, a second electrode formed at the display panel in the peripheral area. In the display device, the first electrode includes a first portion which is opposed to the second electrode and a second portion which is not opposed to the second electrode, and the adhesive layer is interposed between the first portion and the second electrode.

Abstract: A touch detection device includes a substrate, a plurality of drive electrodes arranged on a plane parallel to the substrate and in a first region in which an image is displayed, and a plurality of touch detection electrodes configured to generate a capacitance between the touch detection electrodes and the drive electrodes. At least one touch detection electrode among the touch detection electrodes includes a first part arranged in the first region and a second part arranged in a second region adjacent to the first region. The drive electrodes are sequentially supplied with the first drive signal to detect a conducting body in contact with or close to the first region in a first touch detection mode, and the touch detection electrodes are supplied with a second drive signal to detect a conducting body in contact with or close to the second region in a second touch detection mode.

Abstract: According to one embodiment, a display device includes a display panel having a display area, a first substrate opposed to the display panel, an adhesive layer arranged between the display panel and the first substrate, a first electrode formed at the first substrate in a peripheral area arranged along at least a part of an outer edge of the display area, a second electrode formed at the display panel in the peripheral area. In the display device, the first electrode includes a first portion which is opposed to the second electrode and a second portion which is not opposed to the second electrode, and the adhesive layer is interposed between the first portion and the second electrode.

Abstract: A touch detection device includes a substrate, a plurality of drive electrodes arranged on a plane parallel to the substrate and in a first region in which an image is displayed, and a plurality of touch detection electrodes configured to generate a capacitance between the touch detection electrodes and the drive electrodes. At least one touch detection electrode among the touch detection electrodes includes a first part arranged in the first region and a second part arranged in a second region adjacent to the first region. The drive electrodes are sequentially supplied with the first drive signal to detect a conducting body in contact with or close to the first region in a first touch detection mode, and the touch detection electrodes are supplied with a second drive signal to detect a conducting body in contact with or close to the second region in a second touch detection mode.

Abstract: A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

Abstract: A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

Abstract: The present invention provides a pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent as effective components for the prevention or therapy against atherosclerosis or diseases caused by atherosclerosis.

Abstract: The present invention concerns the hydrochloride of the compound (5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidin-2,4-dione) of the following structure (I) which exhibits an excellent hypoglycemic activity and the like. Said hydrochloride is useful when administered to patients for the treatment and/or prophylaxis of diabetes mellitus, hyperglycemia, impaired glucose tolerance and the like.

Abstract: Amidocarboxylic acid compounds of the formula: 1

Abstract: The &agr;-substituted carboxylic acid derivatives having the formula (I): 1

Abstract: A method for testing a therapeutic or preventive agent for hyperlipidemia, and a nucleic acid probe, a primer, and an antibody which are used in the method. Specifically, a method for testing the effect of a test substance as a therapeutic or preventive agent for hyperlipidemia by expression of a gene having a sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 of the Sequence Listing which participates in regulation of neutral-fat concentration in the blood of a mammal, and a nucleic acid probe, primer or antibody used for the method. The present invention makes it possible to search for a candidate substance for a therapeutic or preventive agent for hyperlipidemia.

Abstract: A method for testing a therapeutic or preventive agent for hyperlipidemia, and a nucleic acid probe, a primer, and an antibody which are used in the method. Specifically, a method for testing the effect of a test substance as a therapeutic or preventive agent for hyperlipidemia by expression of a gene having a sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 of the Sequence Listing which participates in regulation of neutral-fat concentration in the blood of a mammal, and a nucleic acid probe, primer or antibody used for the method. The present invention makes it possible to search for a candidate substance for a therapeutic or preventive agent for hyperlipidemia.

Abstract: A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress inhibitory effects, and is useful as a drug, particularly as a drug for the prevention or treatment of arteriosclerosis. The invention also provides a method for the treatment or prophylaxis of arteriosclerosis by administering in combination (i) at least one of said angiotensin II receptor antagonists or angiotensin converting enzyme inhibitors and (ii) one or more insulin resistance improving agents to a mammal suffering from or susceptible to arteriosclerosis.

Abstract: The &agr;-substituted carboxylic acid derivatives having the formula (I): wherein R1 is an alkyl group, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., A is ═CH-group, etc., B is an oxygen atom, etc., W1 is a C1-C8 alkylene group, W2 is a single bond or a C1-C8 alkylene group, X is a hydrogen atom, etc., Y is an oxygen atom, etc., and Z1 is an alkoxy group, etc., and pharmacologically acceptable salts, esters and amides thereof are useful for treatment and/or prevention of diabetes mellitus, impaired glucose tolerance, gestational diabetes mellitus, or the like. Some of the derivatives of the formula (I) are novel compounds.

Abstract: An amine compound of the formula (I): wherein R1 represents an optionally substituted carbamoyl group, etc., R2 represents a hydrogen atom, etc., R3 represents a C1-C10 alkyl group etc., W1, W2 and W3 are the same or different and each represent a single bond or a C1-C8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a ═CH— group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

Abstract: An amine compound of the formula (I): 1

Abstract: A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

Abstract: The &agr;-substituted carboxylic acid derivatives having the formula (I): 1

Abstract: Amidocarboxylic acid derivatives of the formula: wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; X represents a substituted or unsubstituted aryl group, etc.,; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.; and pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as the active ingredient of pharmaceutical compositions. They may be used to treat specified diseases, including diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.

Abstract: A method for testing a therapeutic or preventive agent for hyperlipidemia, and a nucleic acid probe, a primer, and an antibody which are used in the method. Specifically, a method for testing the effect of a test substance as a therapeutic or preventive agent for hyperlipidemia by expression of a gene having a sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 of the Sequence Listing which participates in regulation of neutral-fat concentration in the blood of a mammal, and a nucleic acid probe, primer or antibody used for the method. The present invention makes it possible to search for a candidate substance for a therapeutic or preventive agent for hyperlipidemia.